CV Sciences Revenue and Competitors
Estimated Revenue & Valuation
- CV Sciences's estimated annual revenue is currently $21.1M per year.
- CV Sciences's estimated revenue per employee is $356,949
- CV Sciences's total funding is $2M.
Employee Data
- CV Sciences has 59 Employees.
- CV Sciences grew their employee count by -12% last year.
CV Sciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $61.1M | 323 | 12% | N/A | N/A |
What Is CV Sciences?
CV Sciences: Integrating Science and Nature, Improving Health and Well-being CV Sciences, Inc., a life sciences organization, is focused on promoting healthy living through their pharmaceutical drug development efforts and portfolio of finished product brands. Makers of PlusCBD Oil, the leading brand in hemp-derived CBD oil products available online, in health food stores, and practitioners offices nationwide. At CV Sciences, our mission is to make healthy people healthier. Our dedication to consumer well-being underscores our values, operations, and products.
keywords:N/A
$2M
Total Funding
59
Number of Employees
$21.1M
Revenue (est)
-12%
Employee Growth %
N/A
Valuation
N/A
Accelerator
CV Sciences News
NEW YORK, April 11, 2022 /PRNewswire/ --. UNITED STATES DISTRICT COURT DISTRICT OF NEVADA. In re: CV SCIENCES, INC. SECURITIES LITIGATION.
CV SCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) · December 31, 2021 , our...
(OTCQB:CVSI) (the Company, CV Sciences, our, us or we), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products,...
SAN DIEGO, Aug. 12, 2019 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent ...
Other Companies in Las Vegas
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $15.3M | 59 | 0% | N/A |
#2 | $18.3M | 59 | -11% | N/A |
#3 | $8.8M | 59 | 34% | N/A |
#4 | $7.5M | 59 | -5% | N/A |
#5 | $16.7M | 59 | 11% | N/A |